Introduction {#S1}
============

Preeclampsia (PE) is generally defined as new hypertension and substantial proteinuria at or after 20 weeks' gestation ([@B1]). Complicating 2--8% of pregnancies, PE is a major cause of severe maternal morbidity and mortality and adverse perinatal outcomes worldwide ([@B2], [@B3]).

In the last 20 years, the incidence of PE has risen in the Western Countries, probably due to an increased prevalence of predisposing factors, such as advanced maternal age, chronic hypertension, diabetes, obesity, and the growing use of assisted reproductive techniques ([@B4], [@B5]).

Despite the great socio-economic impact of PE and the amount of studies carried out in this field, the pathogenic mechanisms leading to PE onset still remains unclear as well as an effective preventive intervention is still lacking ([@B6]).

The placental origins of PE have long been recognized and then formalized in the two stage model of the syndrome ([@B7]). The first stage is represented by inadequate development of the early placenta and its maternal blood supply, called poor placentation, which is established before 20 weeks and before clinical signs appear. During physiological placental development, extensive remodeling of maternal spiral arteries takes place in order to supply increased need of maternal blood in the second two trimesters of pregnancy. That process depends on extravillous cytotrophoblasts that invade the lining of the pregnant uterus from weeks 6 to 18 of gestation, expanding the vascular capacity of the utero-placental circulation ([@B8]). In many cases of PE, trophoblast invasion has been shown to be inadequate with poorly remodeled arteries and reduced capacity of the utero-placental circulation ([@B9]).

In the second stage, a dysfunctional and hypoxic placenta is considered to release factors into the maternal circulation that cause the clinical features of this condition, including hypertension and proteinuria, as well as clotting and liver dysfunction. These appear to arise from a generalized systemic inflammatory response, of which endothelial dysfunction is a prominent component ([@B7]).

Thus, nowadays, one of the biggest challenges in the research field of PE is to identify possible primary triggers of poor placentation, then leading to clinical PE, in order to develop effective preventative interventions. In that scenario, a possible role for infections has been widely suggested.

Epidemiologic Association between *Helicobacter pylori* Infection and Preeclampsia {#S2}
==================================================================================

In the last few years, an epidemiological link between *Helicobacter pylori* (HP) infection and PE has been observed ([@B10]--[@B13]).

*Helicobacter pylori* is a Gram-negative bacterium with a specific tropism for the gastric mucosa ([@B14]); it is the main cause of chronic gastritis and peptic ulcer, as well as a risk factor for MALT-lymphoma and gastric cancer ([@B15]). Only some strains of HP possess determinants of pathogenicity, able to modulate the local and systemic inflammatory response ([@B16]), like the cytotoxin-associated gene-A (CagA), which encodes for a hydrophilic, surface-exposed protein ([@B17]). CagA-positive strains of HP have been shown to induce an inflammatory response in the gastric mucosa greater than that induced by CagA-negative ones ([@B18]). Owing to its capability to stimulate the immune system, HP has also been proposed to play a role in some extra-gastric diseases; in particular, the epidemiological association between HP infection and vascular diseases has been shown, including ischemic heart diseases, primary Raynaud's phenomenon and migraine, all conditions characterized by endothelial dysfunction ([@B19], [@B20]).

Interestingly, anti-CagA antibodies seem to be able to cross-react with antigens localized on the surface of human endothelial cells in either normal or atherosclerotic arteries, thus providing a possible mechanism explaining this association ([@B21], [@B22]).

Daví and co-authors have shown an association between HP infection and high levels of *in vivo* markers of lipid peroxidation and platelet activation, urinary 8-iso-PGF2 and 11-dehydro-TXB2, respectively. Interestingly, successful eradication of HP infection led to a significant reduction in both markers, suggesting a novel mechanism by which an infectious agent could contribute to atherothrombosis ([@B23]).

A few years ago, Ponzetto et al. showed, for the first time, higher seropositivity for HP infection in 47 mothers with PE (51.1%) compared with 47 women with uneventful pregnancy (31.9%). The difference was even greater when considering positivity for CagA-positive strains of HP (80.9 and 14.9%, respectively) ([@B10]).

This epidemiologic association has subsequently been confirmed by several studies ([@B11], [@B13]) (Table [1](#T1){ref-type="table"}), and a correlation between persistent and virulent infections (VacA/CagA seropositive patients) for HP and PE complicated by fetal intrauterine growth restriction (IUGR) has also been shown ([@B13]).

###### 

**Studies investigating the prevalence of HP infection in general, and CagA+ strains HP infection, in particular, in healthy pregnant women (CTR) in comparison with preeclamptic women (PE)**.

  -------------------------------------------------------------------------------
  Authors                       Population\   HP+\   *P*       CagA+\   *P*
                                (*n*)         (%)              (%)      
  ----------------------------- ------------- ------ --------- -------- ---------
  Ponzetto et al. ([@B10])      CTR = 47      31.9             14.9     

                                PE = 47       51.1   0.033     80.9     \<0.001

  UstUn et al. ([@B11])         CTR = 40      12.5             --       --

                                PE = 40       35.0   0.034     --       --

  Pugliese et al. ([@B12])      CTR = 25      32.0             28.0     

                                PE = 25       84.0   \<0.001   80.0     \<0.001

  Cardaropoli et al. ([@B13])   CTR = 49      42.9             22.4     

                                PE = 49       85.7   \<0.001   81.6     \<0.001
  -------------------------------------------------------------------------------

**P* \< 0.05: statistically significant*.

Thus, since the association between HP infection and PE occurrence has been widely confirmed, we hypothesized that this bacterial infection might have a role as possible trigger in the etiopathogenesis of PE.

Anti-CagA Antibodies Class IgG-Mediated Trophoblast Invasion Inhibition: An *In vitro* Model of HP-Induced Poor Placentation {#S3}
============================================================================================================================

To try to answer that question, we investigated whether HP infection might induce an immune humoral response able to trigger an autoantibody-mediated placental cellular damage. In particular, since anti-CagA antibodies are able to cross-react with antigens of endothelial cells ([@B21]) and cytotrophoblast cells show an endothelial origin, we tested murine anti-CagA antibodies class IgG -- the only class of immunoglobulins able to cross placental barrier on human primary trophoblast cultures in order to find a possible cross-reaction. Interestingly, we observed that anti-CagA antibodies are able to bind, on the surface of trophoblast cells, to β-actin protein, one of the main components of cell cytoskeleton ([@B24]). Consistently, immunofluorescence performed on trophoblast cells using either anti-CagA or anti-β-actin antibodies showed an identical pattern of reaction, thus confirming β-actin to be the real cross-reacting protein. Interestingly, actin, in either endothelial or trophoblast cells, is not only important for maintaining the cell structure but it is also crucial for intercellular adhesion ([@B25], [@B26]) and it is now well established that actin-associated adhesions contribute to placental anchorage ([@B26]). We observed that anti-CagA antibodies show a dose-dependent binding activity as well and, as biological effect, a dose-dependent impairment of cytotrophoblast invasiveness *in vitro*, a crucial point for PE development. Furthermore, to better understand the molecular mechanisms involved in the antibody-mediated functional impairment of trophoblast cells, we examined the effect of anti-CagA on ERK activation and NF-kB nuclear translocation, two important factors activated during trophoblast proliferation, and we observed that anti-CagA antibodies are able to inhibit the activation of both elements ([@B24]).

As a whole, these observations provided a possible autoimmune pathogenic mechanism induced by HP infection, negatively interfering with the fetal side of placental development. This pathogenic model of autoimmune-mediated placental impairment is the first one linking HP infection, poor placentation, and PE (Figure [1](#F1){ref-type="fig"}).

![**Supposed mechanism of *Helicobacter pylori* infection-induced molecular mimicry leading to cross-reaction of anti-CagA antibodies to trophoblast cells and poor placentation**.](fimmu-05-00484-g001){#F1}

Discussion {#S4}
==========

Although the cause of PE remains largely unknown, the leading hypotheses strongly rely on disturbed placental function early in pregnancy ([@B27]). Impaired remodeling of the spiral arteries has especially been considered as an early defect causing PE ([@B28]).

Inadequate placentation may lead to impaired intervillous perfusion and to the establishment of placental hypoxic status, causing oxidative stress of trophoblast cells and the release in maternal circulation of anti-angiogenic factors and trophoblast debris, believed to mediate maternal systemic inflammatory response, endothelial dysfunction, and hypercoagulability in PE syndrome ([@B28], [@B29]).

Several studies suggested a strong association between PE and HP infections ([@B10]--[@B13]). Our *in vitro* studies showed an anti-CagA antibody-mediated mechanism of placental impairment at fetal side of early placental development. Thus, it is likely that antibodies directed against bacterial CagA protein might cross-react with antigens expressed on trophoblast cell, and in particular with β-actin, through an immunologic mechanism called molecular mimicry, leading to autoimmune response. This binding could inhibit significantly trophoblast invasiveness, probably negatively interfering with intracellular signaling ad intercellular connections, potentially leading to inadequate placental development. That could represent an intriguing model of infection-induced autoimmune triggering for poor placentation and PE onset, giving an explanation to the higher prevalence of HP infection among women developing PE.

Conclusion {#S5}
==========

More studies are needed to further investigate the impact of HP infection in triggering PE onset or, eventually, in worsening its clinical presentation.

However, it should be considered that, nowadays, in obstetrical practice, diseases with lower incidence than PE, like Rh alloimmunization or Down's syndrome, are commonly screened. Thus, if HP will be confirmed as a contributing factor to PE, it will have important positive implications for the public health system, since the infection is treatable, and the future challenge would be to assess whether pre-pregnancy screening and preventive HP eradication would reduce the incidence of PE or moderate the severity of its clinical presentation.
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